Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13566
Title: Preclinical characterization and in vivo imaging studies of an engineered recombinant technetium-99m-labeled metallothionein-containing anti-carcinoembryonic antigen single-chain antibody.
Austin Authors: Pietersz, Geoffrey A;Patrick, M R;Chester, K A
Affiliation: Austin Research Institute, Austin Hospital, Heidelberg, Victoria, Australia
Issue Date: 1-Jan-1998
Publication information: Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine; 39(1): 47-56
Abstract: We describe the engineering of a novel single-chain fragment (scFv) metallothionein (MET) containing anti-carcinoembryonic antigen (CEA) antibody (referred to as MET-scFv) for use as a diagnostic imaging agent in colorectal cancer.Site-directed cloning of annealed oligonucleotides, containing both the MET and a c-myc tag sequence, into a pUC19-based expression vector enabled soluble secreted protein expression from Escherichia coli. Affinity purification was used to purify the protein using an anti-c-myc affinity column. The specificity of both the unlabeled and labeled MET-scFv for CEA was demonstrated by solid-phase enzyme-linked immunosorbent assay and radioimmunoassay and by fluorescence-activated cell sorting analysis on CEA-expressing human colorectal LS-174T cells. Technetium-99m labeling was achieved using a Zn2+ transchelation step, enabling direct 99mTc transfer without separate reduction of MET. In vitro stability was demonstrated by fast protein liquid chromatography analysis of labeled MET-scFv, incubated with bovine serum albumin (BSA), transferrin and mouse serum. Last, in vivo pharmacokinetics, biodistribution and imaging were performed.Yields of 6 mg/liter induced culture purified protein were achieved. Successful site-specific labeling was demonstrated using a Zn2+ transchelation modification of a pretinning method, which also enabled lower amounts of the reducing agent to be used. The specificity for CEA was retained after labeling. Despite a rapid serum clearance (t(1/2alpha) = 2.8 min), adequate localization to tumor of 5.37% injected dose/g at 4 hr was demonstrated. Moreover, the short-lived t(1/2alpha) of scFv, its early tumor targeting and rapid blood-pool clearance gave tumor-to-blood ratios of 2.07 by 4 hr, enabling early gamma camera imaging. Successful and specific imaging was achieved using LS-174T xenografts in nude mice by 3-6 hr.A recombinant MET containing scFv was successfully expressed, purified and labeled with 99Tc. The stable site-specific labeling of 99Tc, combined with the rapid plasma clearance of the scFv, led to successful early in vivo imaging of xenografted mice.
Gov't Doc #: 9443738
URI: https://ahro.austin.org.au/austinjspui/handle/1/13566
Journal: Journal of Nuclear Medicine
URL: https://pubmed.ncbi.nlm.nih.gov/9443738
Type: Journal Article
Subjects: Animals
Antibodies, Monoclonal.diagnostic use.pharmacokinetics
Carcinoembryonic Antigen.immunology
Colorectal Neoplasms.radionuclide imaging
Female
Genetic Engineering
Humans
Isotope Labeling
Metallothionein.diagnostic use.pharmacokinetics
Mice
Mice, Inbred BALB C
Mice, Nude
Mice, SCID
Neoplasm Transplantation
Radioimmunodetection
Recombinant Proteins.diagnostic use.pharmacokinetics
Technetium.diagnostic use
Tissue Distribution
Appears in Collections:Journal articles

Show full item record

Page view(s)

12
checked on May 29, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.